These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 21982019)

  • 1. HNF1B polymorphism associated with development of prostate cancer in Korean patients.
    Kim HJ; Bae JS; Lee J; Chang IH; Kim KD; Shin HD; Han JH; Lee SY; Kim W; Myung SC
    Urology; 2011 Oct; 78(4):969.e1-6. PubMed ID: 21982019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic variations in VDR associated with prostate cancer risk and progression in a Korean population.
    Oh JJ; Byun SS; Lee SE; Hong SK; Jeong CW; Kim D; Kim HJ; Myung SC
    Gene; 2014 Jan; 533(1):86-93. PubMed ID: 24120391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk.
    Sun J; Wiklund F; Zheng SL; Chang B; Bälter K; Li L; Johansson JE; Li G; Adami HO; Liu W; Tolin A; Turner AR; Meyers DA; Isaacs WB; Xu J; Grönberg H
    J Natl Cancer Inst; 2005 Apr; 97(7):525-32. PubMed ID: 15812078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen receptor beta polymorphism is associated with prostate cancer risk.
    Thellenberg-Karlsson C; Lindström S; Malmer B; Wiklund F; Augustsson-Bälter K; Adami HO; Stattin P; Nilsson M; Dahlman-Wright K; Gustafsson JA; Grönberg H
    Clin Cancer Res; 2006 Mar; 12(6):1936-41. PubMed ID: 16551880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. H6D polymorphism in macrophage-inhibitory cytokine-1 gene associated with prostate cancer.
    Lindmark F; Zheng SL; Wiklund F; Bensen J; Bälter KA; Chang B; Hedelin M; Clark J; Stattin P; Meyers DA; Adami HO; Isaacs W; Grönberg H; Xu J
    J Natl Cancer Inst; 2004 Aug; 96(16):1248-54. PubMed ID: 15316060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single nucleotide polymorphisms in DKK3 gene are associated with prostate cancer risk and progression.
    Kim MS; Lee HN; Kim HJ; Myung SC
    Int Braz J Urol; 2015; 41(5):869-97. PubMed ID: 26689513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of IGFBP3 gene polymorphisms on IGFBP3 serum levels and the risk of prostate cancer in low-risk Korean men.
    Park K; Kim JH; Jeon HG; Byun SS; Lee E
    Urology; 2010 Jun; 75(6):1516.e1-7. PubMed ID: 20350746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association among polymorphisms in the steroid 5alpha-reductase type II (SRD5A2) gene, prostate cancer risk, and pathologic characteristics of prostate tumors in an Ecuadorian population.
    Paz-y-Miño C; Witte T; Robles P; Llumipanta W; Díaz M; Arévalo M
    Cancer Genet Cytogenet; 2009 Mar; 189(2):71-6. PubMed ID: 19215786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic polymorphisms of matrix metalloproteinases: susceptibility and prognostic implications for prostate cancer.
    Dos Reis ST; Pontes J; Villanova FE; Borra PM; Antunes AA; Dall'oglio MF; Srougi M; Leite KR
    J Urol; 2009 May; 181(5):2320-5. PubMed ID: 19303106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer.
    Chen YC; Giovannucci E; Lazarus R; Kraft P; Ketkar S; Hunter DJ
    Cancer Res; 2005 Dec; 65(24):11771-8. PubMed ID: 16357190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of genetic variability within 8q24 on aggressiveness patterns at diagnosis and familial status of prostate cancer.
    Cussenot O; Azzouzi AR; Bantsimba-Malanda G; Gaffory C; Mangin P; Cormier L; Fournier G; Valeri A; Jouffe L; Roupret M; Fromont G; Sibony M; Comperat E; Cancel-Tassin G
    Clin Cancer Res; 2008 Sep; 14(17):5635-9. PubMed ID: 18765558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A haplotype analysis of HER-2 gene polymorphisms: association with breast cancer risk, HER-2 protein expression in the tumor, and disease recurrence in Korea.
    Han W; Kang D; Lee JE; Park IA; Choi JY; Lee KM; Bae JY; Kim S; Shin ES; Lee JE; Shin HJ; Kim SW; Kim SW; Noh DY
    Clin Cancer Res; 2005 Jul; 11(13):4775-8. PubMed ID: 16000574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between methylenetetrahydrofolate reductase C677T and A1298C genotypes and haplotypes and prostate cancer risk and aggressiveness.
    Cicek MS; Nock NL; Li L; Conti DV; Casey G; Witte JS
    Cancer Epidemiol Biomarkers Prev; 2004 Aug; 13(8):1331-6. PubMed ID: 15298954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vitamin D receptor genotypes/haplotypes and prostate cancer risk.
    Cicek MS; Liu X; Schumacher FR; Casey G; Witte JS
    Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2549-52. PubMed ID: 17164384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analysis of the association between the HNF1B rs4430796 (A>G) polymorphism and risk of prostate cancer based on case-control studies.
    Zhao Y; Liang J; Qi JG; Yang N; Wu G; Lin YL; Cao JY; Wang Q; Wang QC
    Genet Mol Res; 2015 Jul; 14(3):7426-35. PubMed ID: 26214421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dietary intake of phytoestrogens, estrogen receptor-beta polymorphisms and the risk of prostate cancer.
    Hedelin M; Bälter KA; Chang ET; Bellocco R; Klint A; Johansson JE; Wiklund F; Thellenberg-Karlsson C; Adami HO; Grönberg H
    Prostate; 2006 Oct; 66(14):1512-20. PubMed ID: 16921512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphisms in the methylenetetrahydrofolate reductase gene and prostate cancer risk.
    Singal R; Ferdinand L; Das PM; Reis IM; Schlesselman JJ
    Int J Oncol; 2004 Nov; 25(5):1465-71. PubMed ID: 15492840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes.
    Gudmundsson J; Sulem P; Steinthorsdottir V; Bergthorsson JT; Thorleifsson G; Manolescu A; Rafnar T; Gudbjartsson D; Agnarsson BA; Baker A; Sigurdsson A; Benediktsdottir KR; Jakobsdottir M; Blondal T; Stacey SN; Helgason A; Gunnarsdottir S; Olafsdottir A; Kristinsson KT; Birgisdottir B; Ghosh S; Thorlacius S; Magnusdottir D; Stefansdottir G; Kristjansson K; Bagger Y; Wilensky RL; Reilly MP; Morris AD; Kimber CH; Adeyemo A; Chen Y; Zhou J; So WY; Tong PC; Ng MC; Hansen T; Andersen G; Borch-Johnsen K; Jorgensen T; Tres A; Fuertes F; Ruiz-Echarri M; Asin L; Saez B; van Boven E; Klaver S; Swinkels DW; Aben KK; Graif T; Cashy J; Suarez BK; van Vierssen Trip O; Frigge ML; Ober C; Hofker MH; Wijmenga C; Christiansen C; Rader DJ; Palmer CN; Rotimi C; Chan JC; Pedersen O; Sigurdsson G; Benediktsson R; Jonsson E; Einarsson GV; Mayordomo JI; Catalona WJ; Kiemeney LA; Barkardottir RB; Gulcher JR; Thorsteinsdottir U; Kong A; Stefansson K
    Nat Genet; 2007 Aug; 39(8):977-83. PubMed ID: 17603485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P53 codon 72 (Arg72Pro) polymorphism and prostate cancer risk: association between disease onset and proline genotype.
    Rogler A; Rogenhofer M; Borchardt A; Lunz JC; Knoell A; Hofstaedter F; Tannapfel A; Wieland W; Hartmann A; Stoehr R
    Pathobiology; 2011; 78(4):193-200. PubMed ID: 21778786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Individual and cumulative association of prostate cancer susceptibility variants with clinicopathologic characteristics of the disease.
    Bao BY; Pao JB; Lin VC; Huang CN; Chang TY; Lan YH; Lu TL; Lee HZ; Chen LM; Ting WC; Hsieh CJ; Huang SP
    Clin Chim Acta; 2010 Sep; 411(17-18):1232-7. PubMed ID: 20450899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.